Following the failure to predict CRS as a severe adverse event induced in Phase I clinical trials by the anti-CD28 monoclonal antibody, TGN1412 (19), several iterations of traditionally used methods and protocols for the detection of cytokine release have been developed to de-risk biotherapeutics. Here, CD28 is linked to congenital rubella syndrome.